MedTrace Logo

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

NCT05302843 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-31

No results posted yet for this study

Summary

This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors

Conditions

  • Metastasis, Neoplasm

Interventions

DRUG

BPI-28592

Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592

Sponsors & Collaborators

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05302843 on ClinicalTrials.gov